Ocugen, Inc. (OCGN)
After hours:
| Previous close | 0.9485 |
| Open | 0.9600 |
| Bid | 0.9789 x 1800 |
| Ask | 1.0100 x 700 |
| Day's range | 0.9354 - 1.0100 |
| 52-week range | 0.3450 - 2.1050 |
| Volume | |
| Avg. volume | 4,152,093 |
| Market cap | 283.54M |
| Beta (5Y monthly) | 3.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1800 |
| Earnings date | 07 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireOcugen to Participate in 2024 Maxim Healthcare Virtual Summit
MALVERN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will join a panel discussion during the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, taking place from Tuesday, October 15 through Thursd
GuruFocus.comOcugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Ocugen Inc (OCGN) extends its financial runway with successful fundraising and regulatory milestones, despite cash reserve declines and ongoing clinical challenges.
- GlobeNewswire
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
MALVERN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical trial evaluating OCU200, a recombinant fusion protein consisting of tumstatin and transferrin, f
